Actualization of Positions of Gliflozins in Treatment Algorithms for Patients with Heart Failure: Chronology of Success
- Authors: Nikulina N.N.1
-
Affiliations:
- Ryazan State Medical University
- Issue: Vol 30, No 3 (2022)
- Pages: 411-421
- Section: Reviews
- URL: https://journals.rcsi.science/pavlovj/article/view/109598
- DOI: https://doi.org/10.17816/PAVLOVJ109598
- ID: 109598
Cite item
Abstract
INTRODUCTION: Despite the efforts of the cardiologic communities to introduce approaches to treatment of heart failure (HF) based on the highest level of evidence, HF remains one of the “least satisfied demands in the therapy of cardiovascular diseases” due to high prevalence, poor prognosis and insufficient use of treatment methods with clinically proven effectiveness. The article considers chronology of study and introduction of sodium-glucose cotransporter 2 inhibitors (syn.: gliflozins; SGLT2is) in clinical practice from the moment of creation of the first drug of this group ― florizin ― and further, stepwise with the change of the therapeutic paradigm as the result of performed clinical trials. Thus, EMPAREG OUTCOME, CANVAS, DECLARE-TIMI 58 studies demonstrated that SGLT2is not only produce a glucosuric effect, but also reduce the development and progression of HF and increase the life expectancy of patients with type 2 diabetes mellitus (DM2) and with reduced left ventricular ejection fraction (LFEF). DAPA-HF, EMPEROR-Reduced studies proved a possibility of improving the outcomes for patients with HF with reduced LVEF irrespective of the presence or absence of DM2, thereby significantly expanding the potential target group for SGLT2is. EMPEROR-Preserved study is the only study of SGLT2is to date (the study drug ― empagliflozin) that has demonstrated high effectiveness of the drug in prevention of cardiovascular mortality and hospitalizations for HF, probably irrespective of LVEF and the existence of DM2. In result, on September 9, 2021, FDA (Food and Drug Administration, USА) assigned the “breakthrough therapy” status to Jardiance® (empagliflozin) drug for treatment of HF with preserved LFEF. EMPA-REG OUTCOME, DAPA-HF, EMPEROR-Reduced, EMPEROR-Preserved, DAPA-CKD studies have shown SGLT2is to slow down the development of the terminal stage of chronic kidney disease. Finally, the main result of EMPULSE study completed in 2022, was the proven clinical benefit of empagliflozin in hospitalized and stabilized patients with acute HF decompensation irrespective of HF status and existence of DM2.
CONCLUSION: From the moment SGLT2is have been introduced in the clinical practice, they rapidly and successfully passed the way from the second-line antidiabetic drugs for which it was just enough not to worsen the prognosis for serious cardiovascular complications, to independent and effective class of drugs for treatment of HF (with class I and IIa recommendations). The totality of clinical trials of empagliflozin showed that empaflorizin is so far the only drug of the SGLT2is group with the proven safety and clinical effectiveness including the influence on the prognosis, in patients with HF irrespective of the LVEF status, presence or absence of DM2, for use in outpatient treatment and in stabilized patients in hospital.
Full Text
##article.viewOnOriginalSite##About the authors
Natal’ya N. Nikulina
Ryazan State Medical University
Author for correspondence.
Email: natalia.nikulina@mail.ru
ORCID iD: 0000-0001-8593-3173
SPIN-code: 9486-1801
MD, Dr. Sci. (Med.), Associate Professor
Russian Federation, RyazanReferences
- Braunwald E. Heart failure: a 70 year Odyssey. European Heart Journal. 2022;43(18):1697–9. doi: 10.1093/eurheartj/ehac058
- Braunwald E. SGLT2 inhibitors: the statins of the 21st century. European Heart Journal. 2022;43(11):1029–30. doi: 10.1093/eurheartj/ehab765
- Von Mering J. Über künstlichen Diabetes. Centralbl Med Wiss.1886;22:31–5.
- Alvarado F, Crane RK. Phlorizin as a competitive inhibitor of the active transport of sugars by hamster small intestine in vitro. Biochimica et Biophysica Acta. 1962;56:170–2. doi: 10.1016/0006-3002(62)90543-7
- Rossetti L, Smith D, Shulman GI, et al. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. The Journal of Clinical Investigation. 1987;79(5):1510–5. doi: 10.1172/JCI112981
- Tsujihara K, Hongu M, Saito K, et al. Na(+)-glucose cotransporter inhibitors as antidiabetics. I. Synthesis and pharmacological properties of 4'-dehydroxyphlorizin derivatives based on a new concept. Chemical & Pharmaceutical Bulletin. 1996;44(6):1174–80. doi: 10.1248/cpb.44.1174
- McMurray JJV, Gerstein HC, Holman RR, et al. Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. The Lancet. Diabetes & Endocrinology. 2014;2(10):843–51. doi: 10.1016/S2213-8587(14)70031-2
- Guidance for Industry. Diabetes Mellitus ― Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. 2008. Available at: https://www.fda.gov/media/71297/download. Accessed: 2022 August 03.
- Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-prevention-diabetes-mellitus- revision_en.pdf. Accessed: 2022 August 03.
- Kobalava ZD, Lazarev PV, Villevalde SV. SGLT2 Inhibitors: Rationale and Perspectives of Use in Heart Failure. Kardiologiia. 2018;(2):42–54. (In Russ). doi: 10.18087/cardio.2018.2.10087
- Packer M, McMurray JJV. Rapid evidence ― based sequencing of foundational drugs for heart failure and a reduced ejection fraction. European Journal of Heart Failure. 2021;23(6):882–94. doi: 10.1002/ejhf.2149
- Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. The New England Journal of Medicine. 2015;373(22):2117–28. doi: 10.1056/NEJMoa1504720
- Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in Type 2 diabetes. The New England Journal of Medicine. 2017;377(7):644–57. doi: 10.1056/NEJMoa161192514
- Rådholm K, Figtree G, Perkovic V, et al. Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program. Circulation. 2018;138(5):458–68. doi: 10.1161/CIRCULATIONAHA.118.034222
- Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. The New England Journal of Medicine. 2019;380(4):347–57. doi: 10.1056/NEJMoa1812389
- McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. The New England Journal of Medicine. 2019;381(21):1995–2008. doi: 10.1056/NEJMoa1911303
- Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. The New England Journal of Medicine. 2020;383(15):1413–24. doi: 10.1056/NEJMoa2022190
- Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. The New England Journal of Medicine. 2021;384(2):117–28. doi: 10.1056/NEJMoa2030183
- Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. The New England Journal of Medicine. 2021;385(16):1451–61. doi: 10.1056/NEJMoa2107038
- Arutyunov GP, Lopatin YuM, Ametov AS, et al. Empagliflozin and heart failure: position paper of the experts on the results of the online meeting and discussion of the EMPEROR-Preserved Trial. Terapevticheskii Arkhiv. 2021;93(12):1491–7. (In Russ). doi: 10.442/00403660.2021.12.201281
- Nassif ME, Windsor SL, Borlaug BA, et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nature Medicine. 2021;27(11):1954–60. doi: 10.1038/s41591-021-01536-x
- McMurray JJV, Wheeler DC, Stefánsson BV, et al. Effect of dapagliflozin on clinical outcomes in patients with chronic kidney disease, with and without cardiovascular disease. Circulation. 2021;143(5):438–48. doi: 10.1161/CIRCULATIONAHA.120.051675
- Packer M, Butler J, Zannad F, et al. Empagliflozin and major renal outcomes in heart failure. The New England Journal of Medicine. 2021;385(16):1531–3. doi: 10.1056/NEJMc2112411
- Kosiborod MN, Angermann CE, Collins SP, et al. Effects of empagliflozin on symptoms, physical limitations, and quality of life in patients hospitalized for acute heart failure: results from the EMPULSE trial. Circulation. 2022;146(4):279–88. doi: 10.1161/CIRCULATIONAHA.122.059725
- Lopatin YuM, Arutyunov GP, Ametov AS, et al. Empagliflozin in patients hospitalized for acute decompensated heart failure: an expert resolution on the discussion of the EMPULSE trial. Russian Journal of Cardiology. 2022;27(3):4945. (In Russ). doi: 10.15829/1560-4071-2022-4945
- Packer M, McMurray JJV. Rapid evidence ― based sequencing of foundational drugs for heart failure and a reduced ejection fraction. European Journal of Heart Failure. 2021;23(6):882–94. doi: 10.1002/ejhf.2149
- Vaduganathan M, Claggett BL, Jhund PS, et al. Estimating lifetime benefits of comprehensive disease ― modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet. 2020;396(10244):121–8. doi: 10.1016/S0140-6736(20)30748-0
- Greene SJ, Butler J, Albert NM, et al. Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry. The Journal of the American College of Cardiology. 2018;72(4):351–66. doi: 10.1016/j.jacc.2018.04.070
- McMurray JJ, Packer M. How should we sequence the treatments for heart failure and a reduced ejection fraction? A redefinition of evidence ― based medicine. Circulation. 2021;143(9):875–7. doi: 10.1161/CIRCULATIONAHA.120.0529
- Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895–e1032. doi: 10.1161/CIR.0000000000001063
- Adhikari R, Jha K, Dardari Z, et al. National trends in use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists by cardiologists and other specialties, 2015 to 2020. Journal of the American Heart Association. 2022;11(9):e023811. doi: 10.1161/JAHA.121.023811
- FDA grants Jardiance® breakthrough therapy designation for heart failure with preserved ejection fraction. September 9, 2021. Available at: https://investor.lilly.com/news-releases/news-release-details/fda-grants-jardiancer-breakthrough-therapy-designation-heart. Accessed: 2022 August 03.
- FDA Grants Empagliflozin Breakthrough Therapy Status for Heart Failure With Preserved Ejection Fraction. Designation based on results from the EMPEROR-Preserved phase III trial. Diagnostic and Interventional Cardiology (DAIC); October 07, 2021. Available at: https://www.dicardiology.com/content/fda-grants-empagliflozin-breakthrough-therapy-status-heart-failure-preserved-ejection. Accessed: 2022 August 03.